Tag: common

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016^® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Clean-label hydration meets real-world functionality in NativePath’s new stick pack assortment featuring natural flavors, third-party tested ingredients, and a complete hydration matrix designed for daily wellness.

NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training

Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The rebrand marks a major milestone following RIV Capital acquisition, signaling FLUENT’s enthusiastic push into the Empire State’s adult-use market

In this 2025 product transparency update, BloodVitals details how its pulse oximeter supports real-time blood vitals tracking through non-invasive technology designed for seniors and at-home wellness users. The release explores the shift toward pain-free health monitoring, the rising demand for accessible oxygen level tools, and the increasing role of pulse oximeters in managing vital signs outside clinical settings.

IRVINE, CA., July 08, 2025 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (Nasdaq: CETY) (the “Company” or “CETY”), a clean energy technology company offering power generation, waste to energy, battery storage, and heat to power solutions to deliver affordable, scalable, and eco-friendly energy, clean fuels, and alternative electricity for a sustainable future, is pleased to announce that its technologies should remain fully eligible for federal clean energy tax incentives following the passage of the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025.